From GlobeNewswire: 2025-05-21 16:30:00

Longevity Health Holdings, Inc. (Nasdaq: XAGE) has received a favorable decision from the Nasdaq Hearings Panel, allowing the company to continue its listing on The Nasdaq Stock Market after the proposed merger with 20/20 BioLabs, Inc. The merger and a 1-for-30 reverse stock split are part of XAGE’s strategic plan to meet Nasdaq’s listing requirements. The Panel granted XAGE an exception to demonstrate compliance with Nasdaq’s initial listing rules by September 2, 2025. XAGE is focused on extending human longevity and healthy aging through regenerative bio-aesthetics, diagnostics, and nutrition products like Carmell Secretome™ and Elevai Exosomes™. 20/20 BioLabs offers innovative laboratory tests for early disease detection and management.



Read more at GlobeNewswire: Longevity Health Holdings Announces Continued Nasdaq